Neuropeptide Y
Also known as: Neuropeptide Tyrosine, Neuropeptide Y, NPY, Pro-NPY
Source Neuropeptide Y at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Neuropeptide Y (NPY) is a 36‑amino‑acid neurotransmitter involved in energy balance, stress response, and vascular tone. It is widely studied in preclinical models but has no approved therapeutic indication.
Mechanism of Action
Activates Y1, Y2, and Y5 G‑protein coupled receptors, influencing cAMP levels and intracellular calcium signaling to regulate appetite, anxiety, and cardiovascular function.
Routes of Administration
Goals & Uses
- Circadian rhythm regulationChronobiology ResearchLow
- Cardiovascular regulationCardiovascular ResearchLow
- Epilepsy / Seizure suppressionNeurology ResearchModerate
- Appetite stimulation / Orexigenic researchMetabolic / Obesity ResearchHigh
- Anxiety modulationPsychiatricModerate
- Anxiety and stress modulationNeuropsychiatric ResearchModerate
- Bone metabolismMusculoskeletal ResearchLow
- Obesity treatmentMetabolicModerate
Contraindications
- Hypertensive crisis riskCardiovascularHigh
- Known hypersensitivity to NPYImmunologicHigh
Adverse Effects
- Injection site reactionsLocalCommon
- HypotensionCardiovascularCommonLow blood pressure
- TachycardiaCardiovascularCommonAbnormally fast heart rate
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Increased appetite / HyperphagiaMetabolicCommon
- Sedation / AnxiolysisNeurologicalUncommon
- Vasoconstriction / HypertensionCardiovascularCommon
- BradycardiaCardiovascularUncommon
Drug Interactions
- Antihypertensive agentsModerate
- Beta‑blockersModerate
- DPP-IV inhibitors (e.g., sitagliptin)Low
- Antihypertensives (ACE inhibitors)Moderate
- Sympathomimetic agents (e.g., norepinephrine)Moderate
Population Constraints
- Pediatric populationsAgeRelative
- pediatric subjectsAgeRelative
- Patients with cardiovascular diseaseComorbidityRelative
- Obese individualsMetabolicRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization; used experimentally.
- United StatesUnapprovedInvestigational use only in research settings.
- United KingdomUnapprovedNot approved by MHRA. Research compound only.
Not approved for clinical use; employed in experimental and preclinical research.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Neuropeptide Y?
Neuropeptide Y (NPY) is a 36‑amino‑acid neurotransmitter involved in energy balance, stress response, and vascular tone. It is widely studied in preclinical models but has no approved therapeutic indication.
What is Neuropeptide Y used for?
Neuropeptide Y is educationally associated with: Circadian rhythm regulation, Cardiovascular regulation, Epilepsy / Seizure suppression, Appetite stimulation / Orexigenic research, Anxiety modulation, Anxiety and stress modulation, Bone metabolism, Obesity treatment. Educational only — not medical advice.
How is Neuropeptide Y administered?
Recorded routes of administration: Intracerebroventricular, Intravenous, Subcutaneous.
What are the potential side effects of Neuropeptide Y?
Reported adverse effects include: Injection site reactions, Hypotension, Tachycardia, Nausea, Increased appetite / Hyperphagia, Sedation / Anxiolysis, Vasoconstriction / Hypertension, Bradycardia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Neuropeptide Y?
Recorded contraindications: Hypertensive crisis risk, Known hypersensitivity to NPY. Consult a qualified clinician before use.